Dextrose Monohydrate 50% Injection Shortage: Current Availability and Manufacturer Updates
According to the U.S. Census Bureau's American Community Survey (ACS) 5-year estimates, the CDC PLACES population-level health analysis, and the CMS Hospital Compare quality data, Areazine publishes editorial articles drawing on more than 19,000 U.S. city profiles. See our methodology for full source attribution and refresh cadence.
The FDA reports a shortage of Dextrose Monohydrate 50% Injection due to manufacturing discontinuations, with some presentations remaining available while others are discontinued.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on February 17, 2026 and geographically references United States. Its severity classification of "medium" signals how the issuing agency weighs the risk of harm if no action is taken — "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to — Drug Shortages — determines the regulatory framework behind it, which shapes what remedies (refunds, replacements, recalls, evacuations) are available to affected individuals and who holds statutory responsibility for enforcement.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to read it as a data point about the issuing system: how quickly FDA detected the hazard, how precise the geographic or product-identifier scope is, and whether similar notices have clustered in the same category or region in the last 90 days. Cluster patterns frequently precede a broader regulatory action — a single localized FDA drug-shortage notice is isolated; three of them within a quarter often indicate a supply-chain, infrastructure, or seasonal driver that will keep producing notices until something structural changes.
For decision-making, Areazine pairs each alert with the original agency URL, the full agency name, and a timestamp so you can verify the notice against the primary source before acting on it. Tags on this item (drug-shortage, fda, medication, Dextrose Monohydrate) map to related alerts in the same area of risk — browsing them together gives a clearer picture than any single notice alone, because the shape of an ongoing issue only becomes visible across multiple sequential alerts.
What's in Shortage
Dextrose Monohydrate 50% Injection (Brand Name: DEXTROSE) is currently listed in a shortage status. This medication is an injection used within the therapeutic categories of Endocrinology/Metabolism, Gastroenterology, and Pediatrics. The shortage was first posted on January 13, 2022, and was last updated on February 12, 2026.
Which Manufacturers Are Affected
The following availability information has been reported for Hospira, Inc., a Pfizer Company:
Hospira, Inc., a Pfizer Company
- Presentation: Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-4902-34)
- Status: Unavailable
- Notes: Discontinuation of the manufacture of the drug.
- Contact: 844-646-4398
Hospira, Inc., a Pfizer Company
- Presentation: Dextrose Monohydrate 50%, Injection, 25 g/50 mL (NDC 0409-6648-02)
- Status: Available
- Contact: 844-646-4398
Why There's a Shortage
The reason provided for the current shortage status is the discontinuation of the manufacture of the drug for specific product presentations.
What Patients Should Do
If you or a family member are prescribed Dextrose Monohydrate 50% Injection, please consider the following steps:
- Consult Your Healthcare Provider: Always speak with your doctor or healthcare professional regarding your treatment plan and any potential impacts this shortage may have on your care. Do not make changes to your medication without professional guidance.
- Speak with Your Pharmacist: Pharmacists can provide the most current information regarding local stock and supply levels.
- Contact the Manufacturer: For specific questions regarding product availability, you may contact Hospira (Pfizer) at 844-646-4398.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Patients should always consult with their healthcare provider for medical guidance and treatment alternatives.
Source
Information sourced from the FDA Drug Shortage Database.
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.
What is this FDA drug-shortage notice about? ▾
Which agency issued this alert? ▾
How severe is this alert? ▾
What area is affected? ▾
Where can I find more Drug Shortages updates? ▾
Primary source data
EPA Outdoor Air Quality Data
Federal monitoring network — every measurement we report
AirNow (EPA / NOAA)
Real-time AQI for every monitored U.S. location
National Weather Service
Active watches, warnings, and advisories — NOAA
CDC Air Quality & Health
Health-impact reference behind every AQI category